- Stocks
- Pharma & Healthcare
- Suraksha Diagnostic
Suraksha Diagnostic share price
NSE: SURAKSHAPharma & HealthcareDiagnostics & Research
Suraksha Diagnostic at a glance
Suraksha Diagnostic (NSE: SURAKSHA) closed at ₹294.05 on 22 Oct 2026, up 1.75% on the day. With a market capitalisation of ₹1,531 Cr, it ranks 1264th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 47.6× trailing earnings, against a return on equity of 13.1% in FY26. Over the past year the share price has risen 1.1%. Its 52-week range is ₹224.10 (30 Mar 2026) to ₹360.00 (21 Sep 2026); the last close is 18.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹81 Cr (+25.1% year on year) and net profit ₹6 Cr (−14.1%), on a consolidated basis. Promoters held 49.10% of the company as of 30 Jun 2026; 0.10% of promoter shares were pledged.
Key numbers
- Market cap
- ₹1,531 CrRank 1264 on NSE
- P/E (trailing)
- 47.6×
- Price to book
- 4.85×FY26
- EPS (TTM)
- ₹6.18to Q4 FY26
- ROE
- 13.1%FY26
- ROCE
- 14.7%FY26
- Debt to equity
- 0.01FY26
- Net profit margin
- 10.1%FY26
- Book value / share
- ₹47.01FY26
- 52-week high
- ₹360.0021 Sep 2026
- 52-week low
- ₹224.1030 Mar 2026
- 1-year return
- +1.1%
- RSI (14-day)
- 36.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.75% | −7.0% | −15.7% | +12.6% | +1.1% |
Suraksha Diagnostic quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹61 Cr | ₹67 Cr | ₹60 Cr | ₹65 Cr | ₹73 Cr | ₹79 Cr | ₹78 Cr | ₹81 Cr |
| Revenue YoY | +17.6% | +11.2% | +14.8% | +17.9% | +19.5% | +17.9% | +30.5% | +25.1% |
| Net profit | ₹8 Cr | ₹10 Cr | ₹6 Cr | ₹7 Cr | ₹9 Cr | ₹9 Cr | ₹7 Cr | ₹6 Cr |
| Net profit YoY | +95.2% | +21.8% | +31.7% | +13.4% | +19.7% | −13.1% | +21.1% | −14.1% |
| Net margin | 12.6% | 15.2% | 10.0% | 11.0% | 12.6% | 11.2% | 9.3% | 7.6% |
| EPS | ₹1.49 | ₹1.94 | ₹1.18 | ₹1.42 | ₹1.80 | ₹1.73 | ₹1.44 | ₹1.21 |
Suraksha Diagnostic financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹223 Cr | ₹190 Cr | ₹219 Cr | ₹252 Cr | — |
| Operating profit | ₹28 Cr | ₹7 Cr | ₹32 Cr | ₹41 Cr | — |
| Net profit | ₹21 Cr | ₹6 Cr | ₹23 Cr | ₹31 Cr | — |
| EPS (₹) | ₹4.00 | ₹1.00 | ₹4.00 | ₹6.00 | — |
| Cash from operations | ₹58 Cr | ₹44 Cr | ₹60 Cr | ₹63 Cr | — |
| Total debt | ₹12 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr | ₹0 Cr |
| Shareholders' equity | ₹144 Cr | ₹154 Cr | ₹178 Cr | ₹211 Cr | ₹245 Cr |
Suraksha Diagnostic shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 48.78% | 48.88% | 48.98% | 49.00% | 49.10% | 49.10% |
| Foreign institutions | 14.46% | 13.95% | 13.72% | 13.46% | 13.46% | 13.47% |
| Domestic institutions | 22.05% | 22.37% | 21.98% | 22.57% | 23.14% | 23.23% |
| Non-institutions | 14.70% | 14.80% | 15.31% | 14.98% | 14.31% | 14.21% |
| Promoter shares pledged | — | — | — | — | 0.10% | 0.10% |
Suraksha Diagnostic vs peers
The listed Pharma & Healthcare companies nearest to Suraksha Diagnostic by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JLHLJupiter Life Line Hospitals | ₹244.75 | −0.87% | −20.0% | ₹1,605 Cr | 8.3 | — |
| ASTECAstec LifeSciences | ₹700.20 | +6.41% | −5.5% | ₹1,560 Cr | — | — |
| SURAKSHASuraksha Diagnostic | ₹294.05 | +1.75% | +1.1% | ₹1,531 Cr | 47.6 | — |
| GKSLGujarat Kidney And Super Speciality | ₹183.00 | +0.53% | — | ₹1,443 Cr | 73.5 | — |
| AMRUTANJANAmrutanjan Health Care | ₹496.20 | +0.45% | −29.1% | ₹1,435 Cr | 24.8 | — |
| JAGSNPHARMJagsonpal Ser | ₹216.03 | −1.13% | +2.0% | ₹1,422 Cr | 34.2 | — |
| TTKHLTCARETTK Healthcare | ₹994.70 | +3.29% | −11.6% | ₹1,406 Cr | 21.4 | — |
Ask anything about Suraksha Diagnostic
Pivot answers on the live chart with evidence you can check, and tests strategies against SURAKSHA's own history. Try: “Why has SURAKSHA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SURAKSHA over five years” · “Compare SURAKSHA with JLHL on margins and valuation”
Frequently asked questions about Suraksha Diagnostic
What is the share price of Suraksha Diagnostic today?
Suraksha Diagnostic (NSE: SURAKSHA) last closed at ₹294.05 on 22 Oct 2026. Its 52-week high is ₹360.00 and its 52-week low is ₹224.10.
What is the market cap of Suraksha Diagnostic?
Suraksha Diagnostic's market capitalisation is ₹1,531 Cr (₹1,531 Cr) at the 22 Oct 2026 close, ranking 1264th among the NSE companies Pivot tracks.
What is the P/E ratio of Suraksha Diagnostic?
Suraksha Diagnostic trades at a trailing P/E of 47.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.8.
What is the ROE and ROCE of Suraksha Diagnostic?
Return on equity was 13.1% in FY26 and return on capital employed was 14.7% in FY26 (consolidated figures).
Is Suraksha Diagnostic a debt-free company?
Suraksha Diagnostic is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.
What were Suraksha Diagnostic's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Suraksha Diagnostic reported revenue of ₹81 Cr, +25.1% year on year, and net profit of ₹6 Cr, −14.1% year on year.
How has Suraksha Diagnostic stock performed over the last year?
Suraksha Diagnostic's share price has risen 1.1% over the past year, +12.6% over three months and −15.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Suraksha Diagnostic?
As of 30 Jun 2026: promoters 49.10%, foreign institutions 13.47%, domestic institutions 23.23%, non-institutions 14.21%. 0.10% of promoter shares were pledged.
Who are Suraksha Diagnostic's competitors?
The listed Pharma & Healthcare companies closest to Suraksha Diagnostic by market cap are Jupiter Life Line Hospitals, Astec LifeSciences, Gujarat Kidney And Super Speciality, Amrutanjan Health Care, Jagsonpal Ser and TTK Healthcare.
Is Suraksha Diagnostic a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Suraksha Diagnostic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SURAKSHA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text